Gilead Finalizes Ouro Medicines Acquisition, Expanding Inflammation Pipeline
GILD sits 24% above its 52-week low of $104.46 on elevated volume (1.9× avg).
Summary
Gilead Sciences and Lakefront have completed the acquisition of Ouro Medicines, a move aimed at further expanding Gilead's inflammation pipeline. This finalizes the deal that was initially reported as nearing completion in late March 2026, with a binding agreement announced shortly thereafter. The acquisition strengthens Gilead's strategic focus on its inflammation portfolio.
At the time of this announcement, GILD was trading at $129.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $160.4B. The 52-week trading range was $104.46 to $157.29. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.